PBYI (Puma Biotechnology) Cyclically Adjusted Revenue per Share: $6.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
53 GF Score
Price $7.69
GF Value $3.34
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Cyclically Adjusted Revenue per Share?

Puma Biotechnology PBYI -3.03% 53 Cyclically Adjusted Revenue per Share is $6.29 as of Mar. 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Puma Biotechnology's adjusted revenue per share for the three months ended in Mar. 2026 was $0.881. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Puma Biotechnology's average Cyclically Adjusted Revenue Growth Rate was -0.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Puma Biotechnology was 58.10% per year. The lowest was -0.80% per year. And the median was 3.05% per year.

As of today (2026-08-04), Puma Biotechnology's current stock price is $7.69. Puma Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $6.29. Puma Biotechnology's Cyclically Adjusted PS Ratio of today is 1.22.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Puma Biotechnology was 67.06. The lowest was 0.29. And the median was 0.98.


Puma Biotechnology  (NAS:PBYI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Puma Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.69/6.29
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Puma Biotechnology was 67.06. The lowest was 0.29. And the median was 0.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Puma Biotechnology Cyclically Adjusted Revenue per Share Related Terms


Puma Biotechnology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Puma Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Puma Biotechnology Cyclically Adjusted Revenue per Share Chart

Puma Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.29 6.41 6.37 6.31 6.25

Puma Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.31 6.29 6.27 6.25 6.29

PBYI vs EVMN, OCGN, EDIT: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Puma Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Cyclically Adjusted PS Ratio falls into.


PBYI
53GF Score
Puma Biotechnology Inc PBYI
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Puma Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Puma Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.881/330.2130*330.2130
=0.881

Current CPI (Mar. 2026) = 330.2130.

Puma Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.163 246.819 0.218
201712 0.576 246.524 0.772
201803 1.764 249.554 2.334
201806 1.342 251.989 1.759
201809 1.646 252.439 2.153
201812 1.861 251.233 2.446
201903 2.574 254.202 3.344
201906 1.395 256.143 1.798
201909 1.449 256.759 1.864
201912 1.605 256.974 2.062
202003 1.304 258.115 1.668
202006 1.765 257.797 2.261
202009 1.279 260.280 1.623
202012 1.318 260.474 1.671
202103 2.401 264.877 2.993
202106 1.319 271.696 1.603
202109 1.133 274.310 1.364
202112 1.350 278.802 1.599
202203 1.084 287.504 1.245
202206 1.312 296.311 1.462
202209 1.253 296.808 1.394
202212 1.418 296.797 1.578
202303 1.119 301.836 1.224
202306 1.156 305.109 1.251
202309 1.174 307.789 1.260
202312 1.503 306.746 1.618
202403 0.908 312.332 0.960
202406 0.975 314.175 1.025
202409 1.638 315.301 1.715
202412 1.198 315.605 1.253
202503 0.922 319.799 0.952
202506 1.046 322.561 1.071
202509 1.070 324.800 1.088
202512 1.462 324.054 1.490
202603 0.881 330.213 0.881

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $6.29 mean?
Puma Biotechnology (PBYI) has a Cyclically Adjusted Revenue per Share of $6.29 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Puma Biotechnology and its competitors.
Is Puma Biotechnology's Cyclically Adjusted Revenue per Share too high?
Puma Biotechnology's current Cyclically Adjusted Revenue per Share is $6.29. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Cyclically Adjusted Revenue per Share compare to EVMN and OCGN?
Puma Biotechnology's Cyclically Adjusted Revenue per Share of $6.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Puma Biotechnology and its competitors. Puma Biotechnology's current Cyclically Adjusted Revenue per Share is $6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $6.29. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Cyclically Adjusted Revenue per Share is $6.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Cyclically Adjusted Revenue per Share: $6.29
  • GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score

Get the complete analysis for PBYI

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.69
Price
$3.34
GF Value